POVETACICEPT, AN ENHANCED DUAL BAFF/APRIL ANTAGONIST, IN AUTOANTIBODY-ASSOCIATED GLOMERULONEPHRITIS

 
POVETACICEPT, AN ENHANCED DUAL BAFF/APRIL ANTAGONIST, IN AUTOANTIBODY-ASSOCIATED GLOMERULONEPHRITIS
James
Tumlin
James Tumlin jtumlin@nephronet.com Emory University School of Medicine and NephroNet Clinical Trials Consortium Nephrology Atlanta
Sreedhar Mandayam samandayam@mdanderson.org University of Texas MD Anderson Cancer Center Nephrology Houston
Arvind Madan amadan@cflks.com Central Florida Kidney Specialists Nephrology Orlando
Frank Cortazar frankcortazar24@gmail.com New York Nephrology Vasculitis and Glomerular Center Nephrology Albany
Sang-Woong Han cardion@hanyang.ac.kr Hanyang University Guri Hospital Nephrology Gyeonggi-do
Hemant Kulkarni hemant.kulkarni@health.wa.gov.au Royal Perth Hospital and Armadale Hospital, East Metropolitan Health Services Nephrology Perth
Jonathan Barratt jb81@leicester.ac.uk University of Leicester Nephrology Leicester
Brad Rovin brad.rovin@osumc.edu The Ohio State University Nephrology Columbus
Hong Zhang hongzh@bjmu.edu.cn Peking University First Hospital Nephrology Beijing
Rupert Davies rupert.davies@alpineimmunesciences.com Alpine Immune Sciences, Inc. R and D Seattle
Amanda Enstrom amanda.enstrom@alpineimmunesciences.com Alpine Immune Sciences, Inc. R and D Seattle
Heather Thomas heather.thomas@alpineimmunesciences.com Alpine Immune Sciences, Inc. R and D Seattle
Jiahua Li Jiahua.li@alpineimmunesciences.com Alpine Immune Sciences, Inc. R and D Seattle
Stanford L. Peng stanford.peng@AlpineImmuneSciences.com Alpine Immune Sciences, Inc. R and D Seattle
Harmeet Singh HSingh@WestNeph.com Western Nephrology Nephrology Arvada